Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by Blue Trust Inc.

Blue Trust Inc. trimmed its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 9.9% in the third quarter, Holdings Channel reports. The firm owned 3,733 shares of the medical equipment provider’s stock after selling 408 shares during the period. Blue Trust Inc.’s holdings in Intuitive Surgical were worth $1,834,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Creekmur Asset Management LLC increased its position in shares of Intuitive Surgical by 200.0% during the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 42 shares during the last quarter. Ridgewood Investments LLC purchased a new position in shares of Intuitive Surgical during the 2nd quarter worth approximately $26,000. Delos Wealth Advisors LLC increased its holdings in Intuitive Surgical by 380.0% in the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 57 shares during the last quarter. LRI Investments LLC purchased a new stake in Intuitive Surgical in the first quarter valued at approximately $30,000. Finally, LGT Financial Advisors LLC raised its position in Intuitive Surgical by 415.4% in the second quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 54 shares during the period. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total value of $19,591,902.12. Following the transaction, the senior vice president now directly owns 3,001 shares of the company’s stock, valued at $1,461,006.84. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, insider Mark Brosius sold 2,115 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $491.91, for a total value of $1,040,389.65. Following the completion of the sale, the insider now directly owns 295 shares of the company’s stock, valued at approximately $145,113.45. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Henry L. Charlton sold 40,243 shares of Intuitive Surgical stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the transaction, the senior vice president now directly owns 3,001 shares in the company, valued at $1,461,006.84. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 53,120 shares of company stock valued at $25,528,753. 0.90% of the stock is owned by corporate insiders.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG opened at $521.15 on Friday. The business has a 50-day moving average of $483.85 and a two-hundred day moving average of $438.17. The company has a market capitalization of $184.85 billion, a price-to-earnings ratio of 94.07, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $523.34.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.24. The firm had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm’s revenue was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.18 earnings per share. As a group, equities research analysts expect that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Evercore ISI reaffirmed a “cautious” rating on shares of Intuitive Surgical in a research note on Friday. Citigroup lifted their target price on Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $380.00 to $510.00 in a research note on Friday, August 2nd. Stifel Nicolaus raised their price objective on shares of Intuitive Surgical from $475.00 to $525.00 and gave the company a “buy” rating in a research note on Friday. Finally, BTIG Research set a $535.00 target price on shares of Intuitive Surgical in a research note on Friday. One research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus target price of $513.74.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.